Total submissions: 1
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Invitae | RCV001065329 | SCV001230285 | pathogenic | Tuberous sclerosis 2 | 2019-04-29 | criteria provided, single submitter | clinical testing | This sequence change results in a premature translational stop signal in the TSC2 gene (p.Arg1745Glnfs*27). While this is not anticipated to result in nonsense mediated decay, it is expected to disrupt the last 63 amino acids of the TSC2 protein. This variant is not present in population databases (ExAC no frequency). This variant has been observed to be de novo in an individual affected with tuberous sclerosis complex (Invitae). This variant disrupts amino acid residues 1746-1751 in TSC2. Deletion of these amino acids (p.His1746_Arg1751del) has been determined to be pathogenic (PMID: 10205261, 15874888, 15024740, 9829910, 11112665, 16114042, 21520333, 21309039). As a result, variants that disrupt these residues are likely to be causative of disease. For these reasons, this variant has been classified as Pathogenic. |